Original Publication Date: 1 April, 2017
Publication / Source: Future Oncology
Authors: Elena Verzoni, Paolo Grassi & Raffaele Ratta
Renal cell carcinoma (RCC) is characterized by high immunogenicity, with a remarkable infiltration of immune cells, especially T cells, natural killer cells, dendritic cells and macrophages . Before the advent of targeted therapy, cytokines including IL-2 and IFN-α were the standard of care in metastatic RCC (mRCC) treatment. Coppin et al. showed that IFN-α was associated with a small survival benefit (3.8 months) . A retrospective analysis of seven Phase II trials testing high-dose IL-2 (HD IL-2) reported more durable responses in selected patients, with an objective response rate (ORR) of 14% including 5% of complete responses .